Key result
Full-dose bivalirudin infusion for 3-4 hours post-PCI reduced NACE rates by 46% and all-cause mortality by 47% compared to unfractionated heparin in patients with acute STEMI.
Why the study?
Does full-dose post-PCI bivalirudin infusion reduce NACEs and mortality compared to UFH in patients undergoing primary PCI for STEMI?
Meta-Analysis (n=16,842)
Does full-dose post-PCI bivalirudin infusion reduce NACEs and mortality compared to UFH in patients undergoing primary PCI for STEMI?
Continuing a full-dose bivalirudin infusion for 3-4 hours post-primary PCI for STEMI significantly reduces net adverse clinical events and mortality compared to unfractionated heparin.
No takes yet. Share an insight, caveat, or question.
Supports full-dose post-PCI bivalirudin continuation in primary PCI; extends RCT meta-analyses confirming optimized dosing benefits.
Shah et al. (2016) conducted a meta-analysis in Acute ST-segment elevation myocardial infarction (n=16,842). Bivalirudin vs. Unfractionated heparin (UFH) was evaluated on Net adverse clinical events (NACEs) and mortality. Full-dose bivalirudin infusion for 3-4 hours post-PCI reduced NACE rates by 46% and all-cause mortality by 47% compared to unfractionated heparin in patients with acute STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: